The observed upregulation of ADAM10 in ALL upon exposure to combination chemotherapy (VCR+MTX) and DOXO suggests a potential drug-induced response with significant ramifications for treatment efficacy and disease progression. Here, ADAM10 is linked to acute lymphoblastic leukemia.